Inactive Instrument

Other languages Intercept Pharmaceuticals, Inc.

Equities

ICPT

US45845P1084

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023	Nov. 13
Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023	Nov. 10
Alfasigma : completa con successo opa su Intercept Pharmaceuticals	Nov. 08
Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc..	Nov. 07
Intercept Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06
Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors	23-10-23
Alfasigma : avvia Opa di Intercept Pharmaceuticals	23-10-11
Sector Update: Health Care Stocks Lower Late Tuesday Afternoon	23-09-26
Sector Update: Health Care Stocks Declining in Afternoon Trading	23-09-26
Intercept Pharmaceuticals Agrees to be Acquired by Alfasigma for $19 Per Share; Stock Soars Pre-Bell	23-09-26
Italy's Alfasigma to buy drugmaker Intercept for nearly $800 mln	23-09-26
Intercept Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02
Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023	23-08-02
Sector Update: Health Care Stocks Lower Late Friday	23-06-23
Sector Update: Health Care Stocks Mixed in Afternoon Trading	23-06-23
Intercept to Cut Workforce in Q3, Discontinue NASH-Related Investment; Study of 747-213 for Biliary Cholangitis Said 'Effective'	23-06-23
Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage	23-06-23
US FDA declines to approve Intercept's fatty liver disease drug	23-06-22
Sector Update: Health Care Stocks Slipping Late Wednesday	23-06-07
Sector Update: Health Care Stocks Falling Wednesday Afternoon	23-06-07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Intercept Pharmaceuticals, Inc.

Equities

ICPT

US45845P1084

Other languages

Filters